Introduction {#s1}
============

Ezrin, a member of the ezrin/radixin/moesin (ERM) family, is an important molecule linking the cytoskeleton to the membrane [@pone.0068527-Bretscher1]. Ezrin is essential for many fundamental cellular processes, including determination of the cell shape, polarity, surface structure, cell adhesion, motility, cytokinesis, phagocytosis, and integration of membrane transport through signaling pathways [@pone.0068527-Bretscher1], [@pone.0068527-Wu1], [@pone.0068527-Ng1], all of which are expected to promote tumor progression. Indeed, recent studies have revealed that ezrin may have an important role in tumorigenesis, development, invasion, and metastasis, probably through regulation of adhesion molecules, participation in cell signal transduction, and signaling to other cell membrane channels in the tumor [@pone.0068527-McClatchey1], [@pone.0068527-Elliott1]. For long a large number of studies have been focused on identifying the prognostic value of Ezrin in solid tumors and most studies suggest that Ezrin is beneficial for tumor growth and, therefore, associated with poor prognosis including carcinomas of the breast [@pone.0068527-Ma1], soft tissue sarcoma [@pone.0068527-Weng1], ovary cancer [@pone.0068527-Moilanen1], Gastrointestinal stromal tumors [@pone.0068527-Wei1],colorectal cancer [@pone.0068527-Patara1] and non-small cell lung cancer [@pone.0068527-Lee1]. In this study, we sought to conduct a meta-analysis to estimate the prognostic importance of Ezrin level for overall survival (OS) and disease-free survival (DFS) among patients with solid tumors, aiming to gain insights into whether Ezrin could provide useful guidance in the biological understanding and treatment of solid tumors.

Materials and Methods {#s2}
=====================

Literature search {#s2a}
-----------------

We conducted a comprehensive search in the Pubmed and Embase to include in the present meta-analysis. We combined search terms for Ezrin expression and solid tumors: ("solid tumor" or "solid cancer") or "Ezrin" or "prognosis". And the last search was updated on 31 Dec 2012. We also reviewed the Cochrane Library for relevant articles. The references cited in those included studies were also reviewed to complete the search.

Study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [@pone.0068527-Moher1].

Inclusion and exclusion criteria {#s2b}
--------------------------------

Inclusion criteria for this study were as follows: (1) proven diagnosis of solid tumor, (2) Ezrin evaluation using immunohistochemical method, (3) association of Ezrin with overall survival (OS), and/or disease-free survival (DFS). Reviews, letters to the editors, and articles published in a book were excluded. We avoided duplication of data by examining the names of all authors and medical centers involved for each article. Authors that published multiple reports on the same sample were included once. We did not weight each study by a quality score because no such score had received general agreement for meta-analysis of observational studies [@pone.0068527-Altman1].

Data extraction {#s2c}
---------------

Two independent reviewers (HK and QWX) read titles and abstracts of all candidate articles. Articles that could not be categorized based on title and abstract alone were retrieved for full-text review. Articles were independently read and checked for inclusion criteria of articles in this study. Any disagreement in quality assessment and data collection was discussed and solved together. The following data were collected: (1) article data including publication date, first author\'s name and country; (2) demographic data regarding inclusion criteria, age, regions, number of patients and number of Ezrin positive; (3) tumor data of Underlying malignancies; (4) survival data including OS, DFS and follow-up period; (5) method of Ezrin measurement, cut-off used for assessing Ezrin positivity. Any differences in the data extraction were resolved together by two authors.

Statistical analysis {#s2d}
--------------------

Hazard ratios (HRs) and its 95% confidence intervals (CIs) were used to estimate the association between Ezrin and patients\' prognosis. For those HRs that were not given directly in the published articles, the published data including the number of patients at risk in each groups, the total number of events and figures from original articles were used to estimate the HR according to the methods described by Parmar et al [@pone.0068527-Parmar1]. If the only exploitable survival data were in the form of figures, we read Kaplan-Meier curves by Engauge Digitizer version 4.1 (free software down-loaded from <http://sourceforge.net>) and extracted survival rate from them to reconstruct the HR and its standard error (SE). All the data analyses were performed with Stata version 11.0 (Stata Corporation, College Station, TX, USA) and we used Q-tests and P-values to estimate the heterogeneity. If P-value was greater than 0.05 which indicated a lack of heterogeneity among studies, a fixed-effects model was used to calculate the HR and its 95%CI according to the method of Mantel and Haenszel [@pone.0068527-Mantel1]. Otherwise, a random-effects model (the DerSimonian-Laird method) was used. By convention, an observed HR\>1 implied a worse prognosis in the Ezrin positive group. The impact of Ezrin on survival was considered to be statistically significant if the 95%CI for the HR did not overlap 1.

Results {#s3}
=======

Study selection and characteristics {#s3a}
-----------------------------------

A total of 126 potentially relevant studies were retrieved electronically, 99 of which were excluded for the reasons shown in [figure 1](#pone-0068527-g001){ref-type="fig"}. Full-text copies of the remaining 43 citations were obtained and were evaluated in more detail. Finally, a total of 27 trials with 4693 patients were available for the meta-analysis.

![Methodological Flow Chart of the Systematic.](pone.0068527.g001){#pone-0068527-g001}

The main features of the eligible studies for Ezrin were summarized in [Table 1](#pone-0068527-t001){ref-type="table"}. The total number of patients included for meta-analysis was 4693, ranging from 40 to 487 per study. In total, 22 studies had data on OS [@pone.0068527-Ma1], [@pone.0068527-Weng1], [@pone.0068527-Moilanen1], [@pone.0068527-Patara1], [@pone.0068527-Lee1], [@pone.0068527-Makitie1], [@pone.0068527-Yeh1], [@pone.0068527-Kobel1], [@pone.0068527-Kobel2], [@pone.0068527-Madan1], [@pone.0068527-Elzagheid1], [@pone.0068527-Gao1], [@pone.0068527-Palou1], [@pone.0068527-Huang1], [@pone.0068527-Aishima1], [@pone.0068527-Lam1], [@pone.0068527-Li1], [@pone.0068527-Wang1], [@pone.0068527-Wang2], [@pone.0068527-Xie1], [@pone.0068527-Jorgren1], [@pone.0068527-Schlecht1], and 7 study have data on DFS [@pone.0068527-Ma1], [@pone.0068527-Wei1], [@pone.0068527-Palou1], [@pone.0068527-MhawechFauceglia1], [@pone.0068527-Kang1], [@pone.0068527-Carneiro1], [@pone.0068527-Korkeila1]. 13 reports originated from Asia, 14 from Non Asia. Number of positive patients ranged from 12 to 240 in the included 27 studies.

10.1371/journal.pone.0068527.t001

###### Main Characteristics of the Eligible Studies.

![](pone.0068527.t001){#pone-0068527-t001-1}

  Author               Year     Region      No of patients              Underlying malignancies               Technology   Positive (%)   Survival analysis   HR estimation         HR (95%)         Cut-off For Ezrin +
  ------------------- ------ ------------- ---------------- ------------------------------------------------ ------------ -------------- ------------------- --------------- ---------------------- ---------------------
  Makitie              2001     Finland          130                    Uveal Malignant Melanoma                 IHC            83               OS                HR           2.52 (1.4--4.51)      at least positive
  Moilanen             2003     Finland          440                       Ovarian carcinoma                     IHC           318               OS                K-M         1.34 (1.06--1.62)            ≥10%
  Weng                 2005     Sweden            50                      soft tissue sarcomas                   IHC            25               OS                K-M         1.48 (0.67--3.28)            \>1%
  Yeh                  2005     Taiwan            84                       pancreatic cancer                     IHC            49               OS                K-M         1.36 (0.98--1.89)      at least moderate
  Kobel                2006     Germany          105                       ovarian carcinoma                     IHC            51               OS                K-M         2.16 (1.31--3.55)      at least moderate
  Kobel                2006     Germany          164                    endometrioid carcinomas                  IHC            83               OS                K-M         1.46 (0.52--4.14)      at least moderate
  Madan                2006       USA             40                             HNSCC                           IHC            19               OS                HR           1.82 (1.0--3.2)             ≥10%
  Mhawech-Fauceglia    2007   Switzerland        108                             HNSCC                           IHC            93               DFS               HR         0.266 (0.63--1.111)     at least moderate
  Elzagheid            2008     Finland           74                       Colorectal cancer                     IHC            61               OS                K-M         1.88 (0.81--4.36)      at least moderate
  Gao                  2009      China           193                      esophageal carcinoma                   IHC            90               OS                HR          1.46 (0.99--2.15)            ≥50%
  Palou                2009      Spain            92                        bladder tumours                      IHC            12               OS                K-M         7.21 (1.43--36.36)           \>20%
                                                                                                                 IHC                             DFS               K-M         4.01 (1.10--14.62)   
  Wei                  2009     Taiwan           347                              GIST                           IHC           229               DFS               HR         2.363 (1.254--4.454)          ≥50%
  Huang                2010     Taiwan            78                       myxofibrosarcomas                     IHC            38               OS                K-M         3.13 (1.34--7.28)      at least moderate
  Kang                 2010      Korea           100                    hepatocellular carcinoma                 IHC            28               DFS               K-M         2.25 (1.41--3.57)            \>10%
  Aishima              2011      Japan            41                intrahepatic cholangiocarcinoma              IHC            20               OS                K-M         1.81 (0.92--3.55)            \>11%
  Carneiro             2011     Sweden           227                      soft tissue sarcomas                   IHC           109               DFS               HR            1.8 (1.1--2.8)       at least moderate
  Korkeila             2011     Finland          176                         Rectal cancer                       IHC            15               DFS               K-M         3.26 (1.09--9.72)      at least moderate
  Lam                  2011    HongKong          150                         Gastric cancer                      IHC           117               OS                HR         2.016 (1.099--2.933)    at least moderate
  Li                   2011      China           436                       Gastric carcinoma                     IHC           236               OS                K-M         2.07 (1.35--3.19)      at least moderate
  Patara               2011     Brazil           250                       Colorectal cancer                     IHC            21               OS                K-M         1.62 (0.75--3.49)      at least moderate
  Wang                 2011      China           200                    nasopharyngeal carcinoma                 IHC           134               OS                K-M         1.96 1.091--2.828)     at least moderate
  Wang                 2011      China            75         Salivary gland adenoid cystic carcinoma (SACC)      IHC            23               OS                HR           2.23 (1.02--4.9)      at least intense
  Xie                  2011      China           307                           Esophageal                        IHC           240               OS                K-M         1.47 (1.08--2.01)      at least moderate
  Jorgren              2012     Sweden           104                         Rectal cancer                       IHC            86               OS                K-M          1.89 (1.16--3.1)      at least moderate
  Lee                  2012      Korea           112                             NSCLCs                          IHC            33               OS                HR         1.853 (1.053--3.623)    at least positive
  Schlecht             2012       USA            123                             HNSCC                           IHC            34               OS                HR          3.11 (1.35--7.15)            ≥10%
  Ma                   2013      China           487                         Breast cancer                       IHC            74               OS                HR         3.711 (3.112--4.371)          ≥75%
                                                                                                                                                 DFS               HR         3.805 (3.002--4.386)  

HR hazard ratio, K-M Kaplan Meier, OS overall survival, DFS disease free survival, IHC immunohistochemical.

Publication bias {#s3b}
----------------

NoevidenceofpublicationbiaswasdetectedfortheHR of OS and PFS in this studybyeitherBeggorEgger\'stest(HRofOS:Begg\'stestp = 0.085,Egger\'stestp = 0.455;HR of PFS: Begg\'stestp = 0.293,Egger\'stestp = 0.764) ([Fig. 4](#pone-0068527-g004){ref-type="fig"} and [Fig. 5](#pone-0068527-g005){ref-type="fig"}).

Meta-analysis {#s3c}
-------------

The results of the meta-analysis were shown in [Fig. 2](#pone-0068527-g002){ref-type="fig"} and [Fig. 3](#pone-0068527-g003){ref-type="fig"}. The combined HR for 22 studies evaluating Ezrin overexpression on OS was 1.95, (95% CI: 1.60--2.39), suggesting that Ezrin overexpression was an indicator of poor prognosis for solid tumor. Significant heterogeneity was observed among the studies. (Q = 55.4, I2 = 62.1%, P\<0.001). When grouped according to geographic settings of individual studies, the combined HRs of Asian studies and non-Asian studies were 2.006 (95% CI: 1.483--2.529) and 1.498 (95%CI: 1.260--1.735) respectively. Subgroupanalysiscouldhelpusdiscoverpotentialinformation of what the clinicians were interested in. Therefore, we studied some factors that might be related with survival. The studies from the tumor types, regions, patients\' number and publication year were considered as the subgroup analysis factors. Finally, all subgroup analyses favored Ezrin overexpression be associated with poor OS ([Table 2](#pone-0068527-t002){ref-type="table"}). 7 studies evaluating Ezrin overexpression on PFS was 2.30, (95% CI: 1.00--3.61), indicate that Ezrin overexpression was an indicator of poor prognosis for solid tumor using random effect model(Q = 96.05, I2 = 92.1%, P\<0.001).

![Ezrin expression and OS.](pone.0068527.g002){#pone-0068527-g002}

![Ezrin expression and PFS.](pone.0068527.g003){#pone-0068527-g003}

![Begg\'s test result of OS.](pone.0068527.g004){#pone-0068527-g004}

![Egger\'s test result of OS.](pone.0068527.g005){#pone-0068527-g005}

10.1371/journal.pone.0068527.t002

###### Stratified analysis of pooled hazard ratios of cancer patients with Ezrin expression.

![](pone.0068527.t002){#pone-0068527-t002-2}

  Stratified analysis         No. of studies   No. of patients    Pooled HR (95%CI)    Heterogeneity  
  -------------------------- ---------------- ----------------- --------------------- --------------- ---------
  **Tumor type**                                                                                      
  **Head and neck cancer**          5                568         2.070(1.488--2.652)        0%          0.894
  **Digestive cancer**              9               1639         1.565(1.325--1.806)        0%          0.871
  **Other types**                   8               1478         2.255(1.131--3.379)       87.3        \<0.001
  **Region**                                                                                          
  **Asian**                         11              2163         2.006(1.483--2.529)       77.1        \<0.001
  **Non Asian**                     11              1572         1.498(1.260--1.735)        0%          0.726
  **No. of patients**                                                                                 
  **≥150**                          9               2627         1.518(1.320--1.717)       33.5         0.150
  **\<150**                         13              1108         1.694(1.386--2.002)        0%          0.874
  **Publication year**                                                                                
  **\<2009**                        10              1372         1.437(1.232--1.642)        0%          0.819
  **≥2010**                         12              2363         2.150(1.611--2.688)       67.9        \<0.001

Discussion {#s4}
==========

Ezrin is a member of the ERM (Ezrin, Radixin and Moesin) family, which was first described as linkers between membrane proteins and actin filaments. It has been implicated in the determination of cell shape, membrane organization, cell polarization, migration, division and they participate in various signaling pathways [@pone.0068527-Elliott1], [@pone.0068527-Khanna1], [@pone.0068527-Curto1]. Alterations of ezrin expression can mediate many changes in the metastasis-associated cell surface signals and intra-cellular signaling cascade that confer the metastatic capability in tumor cells. Therefore, it is conceivable that ezrin overexpression and/or deregulation could contribute to the metastatic behaviors of tumors. Evidence from both animal models and prospective human studies show correlations between ezrin expression levels and tumor progression [@pone.0068527-Khanna1], [@pone.0068527-Yu1], consistent with a crucial role for ezrin in tumor dissemination.

Meta-analysis is useful to integrate results from independent studies for a specified outcome. Pooled results from the combining relevant studies are statistical powerful, and make it possible to detecting effects that may be missed by individual studies.To date, no meta-analysis has been undertaken for any studies that evaluate Ezrin as a prognostic marker in solid tumor. In this meta-analysis, 27 eligible studies that compared the survival of solid tumor according to Ezrin expression level of the primary tumor met the enrollment criteria. The data were organized according to disease-free and overall survival; then combined results demonstrated that Ezrin overexpression was associated with a poor OS (HR, 1.95; 95%CI, 1.60--2.39; P\<0.001.) and PFS (HR, 2.30; 95%CI, 1.00--3.61; P = 0.001.) in solid tumor using a random effect. Due to significant heterogeneity among included studies, we then perform a subgroup analysis according to tumor types, regions, patients\' number and publication year. Allsubgroup analysesfavoredEzrin overexpression be associated with poorOS. In all our data helped to clarify the results of individual studies and to identify patients at high risk for whom specific- or adjuvant-therapy might be necessary since Ezrin overexpression is a prognostic factor for solid tumor.

There is significant heterogeneity among included studies in this systematic review, although we used random-effects models during pooling data of subgroup. The heterogeneity in these studies could be explained by different characteristics of included patients, or differences in the techniques used to detect alterations in Ezrin expression, including antigen retrieval methods, choice of Ezrin antibody, dilutions of the antibodies, and revelation protocols. What\'s more, different sample types including tissue microarray (TMA) and the whole section might also contribute to the heterogeneity because it is possible that more false-negative cases are obtained in TMA than the whole section. Finally, the differences of methodology among included studies also were sources of heterogeneity and caused selection biases potentially [@pone.0068527-Garcia1].

Several important limitations need to be considered when interpreting our analysis. First of all, the number of included studies was relatively small with only about 4693 cases. Patients had received different treatments; preoperative TNM category and histologic types were various. Whereas, we were unable to assess these potential confounders present in individual studies. Second, although we tried to identify all relevant data, potential publication bias was unavoidable and some data could still be missing. Third, although immunohistochemistry was the most commonly applied method for detecting Ezrin in situ, RT-PCR method had also been used for the evaluation of the levels of Ezrin gene or mRNA expression in tumor tissue. Studies measuring Ezrin gene or mRNA level by RT-PCR was not yet included in this meta-analysis. Moreover the cutoff value was defined differently (1%, 10%, 20%, 50%, 75%) in these studies, leading to between-study heterogeneity. Thus we had adopted random effect model and subgroup sensitivity analyses to adjust for the shortcomings.

Finally,this study was constrained to studies published in English language .Although we detected no evidence of publication bias using the graphical method, it was difficult to completely rule out this possibility.

In summary, this present study shows a significant correlation between Ezrin expression and OS as well as DFS rate in solid tumor patients. Ezrin may have prognostic significance for patients with solid tumor based on currently obtained data.However,one should be cautious when interrupting these results due to the limitations of our studies.Further high-quality studies are still needed to confirm these results.
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